Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes

Article English OPEN
Norman, Jessica L; Fixen, Danielle R; Saseen, Joseph J; Saba, Laura M; Linnebur, Sunny A;
  • Publisher: SAGE Publishing
  • Journal: SAGE Open Medicine,volume 5 (issn: 2050-3121, eissn: 2050-3121)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1177/2050312117707687, pmc: PMC5423710
  • Subject: Original Article | Zolpidem | R5-920 | drug safety | Medicine (General) | sleep initiation and maintenance disorders | United States Food and Drug Administration | insomnia
    mesheuropmc: psychological phenomena and processes | musculoskeletal, neural, and ocular physiology

Background: Women have higher morning serum zolpidem concentrations than men after taking an evening dose, potentially leading to increased risk of harm. On 19 April 2013, the United States Food and Drug Administration required labeling changes for zolpidem, recommendin... View more
Share - Bookmark